HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial-Reference-Cited by-同舟云学术

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

Published:2022-11 Issue: Volume:85 Page:104320
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Guarneri Valentina,Brasó-Maristany Fara,Dieci Maria Vittoria,Griguolo Gaia,Paré Laia,Marín-Aguilera Mercedes,Miglietta Federica,Bottosso Michele,Giorgi Carlo Alberto,Blasco Paula,Castillo Oleguer,Galván Patricia,Vivancos Ana,Villagrasa Patricia,Parker Joel S.,Perou Charles M.,Conte PierFranco,Prat Aleix^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference33 articles.

1. GLOBOCAN 2020 breast cancer fact sheet,2021

2. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials;Bradley;Lancet Oncol,2021

3. Dissecting the biological heterogeneity of HER2-positive breast cancer;Schettini;Breast,2021

4. Current and future management of HER2-positive metastatic breast cancer;Martínez-Sáez;JCO Oncol Pract,2021

5. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers;Ferrari;Nat Commun,2016

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tiron enhances the anti-cancer activity of doxorubicin in DMBA-induced breast cancer: Role of Notch signaling/apoptosis/autophagy/oxidative stress;Food and Chemical Toxicology;2024-11

2. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

3. Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer;Current Opinion in Oncology;2024-07-25

4. Use of MRI Radiomics Models in Evaluating the Low HER2 Expression in Breast Cancer;Current Medical Imaging Reviews;2024-07-19

5. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial;Clinical Cancer Research;2024-07-12